The risk model we developed, utilizing five risk signatures (ITGA5, MMP14, FN1, COL5A1, and COL6A1) associated with CAF, holds promise for predicting GBM prognosis and guiding treatment decisions for patients. The gene discussed is ITGA5; the disease is glioblastoma.